©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pathophysiol. Aug 22, 2024; 15(4): 93606
Published online Aug 22, 2024. doi: 10.4291/wjgp.v15.i4.93606
Published online Aug 22, 2024. doi: 10.4291/wjgp.v15.i4.93606
Team players in the pathogenesis of metabolic dysfunctions-associated steatotic liver disease: The basis of development of pharmacotherapy
Shahid Habib, Department of Hepatology, Liver Institute PLLC, Tucson, AZ 85712, United States
Author contributions: Shahid H is responsible for hypothesis creation, data collection, critical data review and synthesis, manuscript writing and submission.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Shahid Habib, FCPS, MBBS, MRCP, Researcher, Department of Hepatology, Liver Institute PLLC, 2830 N Swan Road, Suite 180, Tucson, AZ 85712, United States. shabib@liverinstitutepllc.org
Received: March 1, 2024
Revised: May 14, 2024
Accepted: July 23, 2024
Published online: August 22, 2024
Processing time: 173 Days and 11.4 Hours
Revised: May 14, 2024
Accepted: July 23, 2024
Published online: August 22, 2024
Processing time: 173 Days and 11.4 Hours
Core Tip
Core Tip: The pathogenesis of metabolic dysfunctions associated steatotic liver disease (MASLD) is complex and a thorough analysis of the contributing factors to disease progression is pivotal to individualized patient care. Understanding and identifying the key pathogenic processes responsible for MASLD in each patient allows for the utilization of appropriate and effective pharmacotherapy. This review details the various key players in MASLD pathogenesis, through the lens of carbohydrate and fat metabolism, to divulge new areas of focus that could strengthen the capability of precision medicine for this population of patients.